Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE recommends BMS’ Opdivo-Yervoy combination for RCC

pharmaceutical-technologyApril 09, 2019

Tag: BMS , NICE , NHS , RCC , cancer

PharmaSources Customer Service